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Inhibition of myostatin- and activin-mediated SMAD2/3 signaling using ligand traps,
such as soluble receptors, ligand-targeting propeptides and antibodies, or follistatin
can increase skeletal muscle mass in healthy mice and ameliorate wasting in models
of cancer cachexia and muscular dystrophy. However, clinical translation of these
extracellular approaches targeting myostatin and activin has been hindered by the
challenges of achieving efficacy without potential effects in other tissues. Toward the
goal of developing tissue-specific myostatin/activin interventions, we explored the ability
of transmembrane prostate androgen-induced (TMEPAI), an inhibitor of transforming
growth factor-β (TGF-β1)-mediated SMAD2/3 signaling, to promote growth, and counter
atrophy, in skeletal muscle. In this study, we show that TMEPAI can block activin
A, activin B, myostatin and GDF-11 activity in vitro. To determine the physiological
significance of TMEPAI, we employed Adeno-associated viral vector (AAV) delivery
of a TMEPAI expression cassette to the muscles of healthy mice, which increased
mass by as much as 30%, due to hypertrophy of muscle fibers. To demonstrate that
TMEPAI mediates its effects via inhibition of the SMAD2/3 pathway, tibialis anterior (TA)
muscles of mice were co-injected with AAV vectors expressing activin A and TMEPAI.
In this setting, TMEPAI blocked skeletal muscle wasting driven by activin-induced
phosphorylation of SMAD3. In a model of cancer cachexia associated with elevated
circulating activin A, delivery of AAV:TMEPAI into TA muscles of mice bearing C26 colon
tumors ameliorated the muscle atrophy normally associated with cancer progression.
Collectively, the findings indicate that muscle-directed TMEPAI gene delivery can
inactivate the activin/myostatin-SMAD3 pathway to positively regulate muscle mass in
healthy settings and models of disease.
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INTRODUCTION
Myostatin, activin A, activin B, and GDF11 comprise a subgroup
within the transforming growth factor-β (TGF-β) family of
proteins that is of great interest in the field of skeletal muscle
biology (Chen et al., 2016a). These secreted ligands negatively
regulate the morphogenesis and growth of skeletal muscle by
binding to activin type II receptors (ActRIIA or ActRIIB),
and then recruiting and activating type I receptors (ALK4
or ALK5; Chen et al., 2016a). Activated type I receptors
initiate signaling via SMAD2/3 transcription factors, which
limit muscle growth via effects on both protein synthesis and
protein degradation pathways. Expression of myostatin or activin
A is sufficient to inhibit anabolic signaling associated with
Akt/mTOR activity (Amirouche et al., 2009; Chen et al., 2014).
Concurrently, SMAD2/3 activation regulates the expression
of the E3 ubiquitin ligases MuRF-1 and Atrogin-1 (Sartori
et al., 2009; Lokireddy et al., 2011; Goodman et al., 2013),
which mediate ubiquitination and proteasomal degradation of
myofibrillar proteins, such as myosin (Clarke et al., 2007;
Fielitz et al., 2007). Ultimately, these ActRIIA/B ligands regulate
genes associated with muscle protein turnover, metabolism,
and sarcomere function (Chen et al., 2015, 2017) that are
transcriptionally indicative of muscle wasting associated with
cancer cachexia (Baker et al., 2010; Johnston et al., 2015; Rovira
Gonzalez et al., 2019).
While physiological activity of these TGF-β ligands
contributes to the homeostatic maintenance of muscle mass
(Chen et al., 2017), elevated circulating levels are highly
catabolic, inducing significant muscle wasting in murine
models. For example, elevating systemic levels of myostatin,
activin A or GDF11, by injecting Chinese hamster ovary
(CHO) cells expressing these proteins into the quadriceps
of athymic nude mice, results in a global decline in skeletal
muscle mass of >20% within 12 days (Zimmers et al., 2002,
2017; Walton et al., 2019). Similar results can be observed
when adeno-associated viral vectors (AAV vectors) delivered
to the muscles of mice are used to elevate circulating activin A
levels (Chen et al., 2014). These findings are significant because
these SMAD2/3-activating ligands, particularly activin A and
activin B, are elevated in many chronic conditions where muscle
wasting is observed, including cancer, sepsis, lung disease,
and heart disease (Michel et al., 2003; Yndestad et al., 2004,
2009; Loumaye et al., 2015, 2017). Tellingly, high activin A/B
levels are predictive of adverse outcome in patients with acute
respiratory failure (de Kretser et al., 2013). Thus, concerted
efforts have been directed toward developing therapies that
can block SMAD2/3 activity and preserve muscle mass in
chronic disease.
To date, soluble activin type II receptors (sActRIIA, sActRIIB),
ligand-targeting antibodies, and follistatin have proven the
most efficacious therapeutic reagents in mice (Zhou et al.,
2010; Winbanks et al., 2012; Latres et al., 2017), and humans
(Attie et al., 2013; Campbell et al., 2017). These molecules
potently antagonize signaling by activin-related ligands and
reverse muscle wasting in cancer cachexia models (Li et al.,
2007; Benny Klimek et al., 2010; Zhou et al., 2010). However,
a recent phase II clinical trial using sActRIIB in patients
with muscular dystrophy was halted when some participants
experienced bleeding from mucosal surfaces (Campbell et al.,
2017). This side-effect likely arises from sActRIIB inhibiting
the anti-angiogenic properties of multiple TGF-β ligands (David
et al., 2007) and highlights a problem associated with the use of
systemically-administered pleiotropic antagonists to treat muscle
wasting conditions.
An alternative approach is to identify cytoplasmic/membrane-
associated skeletal muscle proteins that may inhibit SMAD2/3
activation. To this end, we recently identified Pmepa1 as a
transcriptional target of activin A signaling in skeletal muscle
(Chen et al., 2014). Pmepa1 encodes the transmembrane prostate
androgen-induced (TMEPAI) protein, which is expressed in
many tissues. Elevated expression of TMEPAI has been
identified in tumor biopsies and cell lines derived from
patients with prostate, colorectal, breast, ovarian, lung and
kidney cancers (Xu et al., 2000; Rae et al., 2001; Brunschwig
et al., 2003; Giannini et al., 2003). Evidence indicates that
TMEPAI expression in these tumors acts to counteract cell
proliferation (Singha et al., 2014; Fournier et al., 2015;
Li et al., 2015; Du et al., 2018; Abdelaziz et al., 2019),
but this activity is highly dependent on tumor origin (Rae
et al., 2001; Giannini et al., 2003; Vo Nguyen et al., 2014;
Singha et al., 2019).
TMEPAI exerts its activity, in part, by inhibiting the SMAD2/3
signaling pathway, at the level of the plasma membrane
(Watanabe et al., 2010). To date, this action of TMEPAI has only
been demonstrated in relation to TGF-β1 signaling (Watanabe
et al., 2010; Nakano et al., 2014). In this context, TMEPAI
competes with the adaptor protein Smad anchor for receptor
activation (SARA) for binding to SMAD2. This competition
prevents SARA from recruiting SMAD2 to the TGF-β type
I receptor (TβR1/ALK5) and, thereby, reduces the TGF-β1
transcriptional response (Watanabe et al., 2010). TMEPAI exerts
this activity via a short SMAD-inhibitory domain (SIM), which
lies within its C-terminal cytoplasmic region. Targeted disruption
of the SIM domain inhibits the ability of TMEPAI to block TGF-
β1-mediated SMAD2/3 signaling. The SIM domain in TMEPAI
is flanked by two “PY” motifs (PPXY), which are dispensable
for inhibition of TGF-β1 signaling but required for regulation of
Akt signaling pathways (Watanabe et al., 2010). Although there is
some evidence to support that TMEPAI is capable of also blocking
activin A-mediated biological effects (Watanabe et al., 2010), the
extent to which TMEPAI can regulate signaling mechanisms in
skeletal muscle has not been determined.
In this study we aimed to test the hypothesis that TMEPAI
can attenuate myostatin/activin signaling in skeletal muscle
fibers to promote hypertrophy and attenuate muscle wasting.
We generated an AAV vector expressing TMEPAI and tested
its capacity to increase muscle mass following intramuscular
injection in healthy mice, and to preserve muscle mass in
settings of muscle wasting associated with increased activin A
expression. Our studies provide the first evidence that muscle-
directed expression of TMEPAI can attenuate the atrophic actions
of activin/myostatin activity with beneficial consequences for the
maintenance of skeletal muscle mass.
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MATERIALS AND METHODS
Generation of TMEPAI Constructs
A pCDNA 3.1 mammalian vector comprising the full length
human TMEPAI sequence (reference sequence NM_020182.4)
was obtained from GenScript (New Jersey, United States). A C-
terminal polyhistidine-tag (8x histidine) was first introduced
by PCR, to facilitate downstream purification of TMEPAI.
The polyhistidine-tag was incorporated by PCR using an
N-terminal TMEPAI primer (sense sequence 5′-CTAGAAGCTT
ATGCACCGCTTGATGGGGGTCAACAGCAC-3′) with a
C-terminal poly-histidine primer (anti-sense sequence 5′-CTA
GGCGGCCGCCTAATGATGGTGGTGATGGTGATGATGGAG
AGGGTGTCCTTTCTGTTTATCCTTCTCTTTGCTCCAGATG
GC-3′). The primers incorporated restriction sites for HindIII
and NotI, respectively, to enable insertion of the resulting
TMEPAI+HIS PCR product into these sites of the pCDNA
3.1 vector. Point mutations in the PY-domains of TMEPAI
were generated using the Quik-Change Lightning mutagenesis
kit (Agilent Technologies), according to the manufacturer’s
guidelines. Primers used for this mutagenesis were as follows:
TMEPAI-SIM (sense 5′-GGTGCGCGCACCCGCTGCAAGAAC




and TMEPAI-PY2 (sense 5′-GCCGCCGCCCACCGCTAGCG
AGGTCATCG-3′ and anti-sense 5′-CGATGACCTCGCTAGCG
GTGGGCGGCGGC-3′). Introduced mutations were confirmed
using DNA sequencing.
Expression of TMEPAI Variants in
HEK293T Cells
Production of TMEPAI protein variants was verified by transient
transfection in human embryonic kidney (HEK293T) cells
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum (FCS), 100 mM
sodium pyruvate and 1% penicillin/streptomycin (all reagents
from Thermo Fisher Scientific, Massachusetts, United States). For
transfection, HEK293T cells were plated at 8 × 105 cells/well
in 6-well plates and incubated overnight at 37◦C. The following
day, 5 µg of TMEPAI construct DNA was combined with
Lipofectamine 2000 (Thermo Fisher Scientific) in OPTI-MEM
media and added to the cells as outlined by the manufacturer.
Following a 24-h incubation, the cells were lysed for western blot
analysis (as described below).
Assessment of TMEPAI Bioactivity
in vitro
The ability of TMEPAI to block SMAD2/3-mediated ligand
signaling was assessed in a HEK293T luciferase bioassay. In
brief, HEK293T cells were first seeded into a 48-well plate at
a density of 7.5 × 104 cells/well in DMEM containing 10%
FCS (without antibiotics). At 24 h post-plating, cells were
transfected with the SMAD2/3-responsive A3-Luciferase reporter
construct and FAST2 transcription factor (Liu et al., 1999) as
well as increasing amounts of either wild-type or mutant
TMEPAI constructs (0–9 ng/well), using Lipofectamine 2000
(Thermo Fisher Scientific). At 24 h post-transfection, cells
were treated with 200 pM of various SMAD2/3 activating
ligands (myostatin, activin A, activin B, and GDF11, all sourced
from R&D Systems, Minnesota, United States, or TGF-β1
from PeproTech, United States). The following day, cells were
harvested in solubilisation buffer (1% Triton X-100, 25 mM
glycylglycine, pH 7.8, 15 mM MgSO4, 4 mM EGTA, and
1 mM dithiothreitol), and the SMAD2/3-induced luciferase
activity was determined. Luciferase activity was determined as
a % control of the ligand stimulated cells. Ligand treatments
typically resulted in a 10- to 30-fold increase in basal luciferase
activity. Total Area Under the Curve was compared for mutant
TMEPAI forms (SIM and PY1 + PY2) relative to wild type
TMEPAI luciferase activities. Values are total area ± standard
error. Significance was determined using two-way ANOVAs with
Tukey’s Post Hoc analysis.
To support this analysis, the inhibition of ligand-mediated
phosphorylation of SMAD2 and SMAD3 by the TMEPAI variants
was determined by western blot. In brief, HEK293T cells were
plated at 4 × 105 cells/well in 12-well plates in DMEM media
with 10% FCS (without antibiotics). The following day, the cells
were transfected with TMEPAI constructs (0 or 1 µg DNA/well)
using Lipofectamine 2000. After a 24-h incubation, cell culture
media was replaced with low serum media (DMEM, 0.2% FCS
and 50 mM HEPES) and incubated for 4 h at 37◦C to suppress
basal activation of pSMAD2/3. Cells were then treated with
200 pM activin A or TGF-β1 (diluted in low serum media)
and incubated for 45 min. The treated HEK293T cells were
subsequently processed for western blotting as described below.
Western Blotting
HEK293T cells were lysed in ice cold RIPA buffer (10 mM
Tris-Cl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS and 140 mM NaCl, pH
8.0) containing Complete protease inhibitors and PhosStop
phosphatase inhibitors (both Roche Applied Sciences). Skeletal
muscles were homogenized in ice cold lysis buffer containing
50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10% glycerol,
1% SDS, 1% Triton X-100, and phosphatase (P5726, Sigma
Aldrich, Missouri, United States) and protease (P8340, Sigma)
inhibitors. Following lysis, samples were rotated for 20 min
at 4◦C, incubated at 70◦C for 10 min with frequent mixing
and centrifuged at 18,000 g for 20 min at 4◦C. The protein
concentration of resulting supernatants was determined using
a BCA protein assay (Thermo Fisher Scientific), samples were
reduced with a final concentration of 2.5% β-mercaptoethanol
and then denatured for 5 min at 95◦C. Protein fractions
were resolved by SDS-PAGE using pre-cast 10% Tris-Glycine
(Bio-Rad, California, United States) or 4–12% Bis-Tris gels
(Thermo Fisher Scientific), blotted onto nitrocellulose or PVDF
membranes (Bio-Rad), blocked for a minimum of 1 h in either
5% skim milk powder or 1% BSA in TBS-T (50 mM Tris, 150 mM
NaCl, 0.05% Tween-20, pH 8.0) and incubated overnight at 4◦C
in primary antibody solutions. All primary antibodies were
used at a dilution of 1:1000 unless otherwise stated. Antibodies
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against pSmad2Ser465/467 (#3101), total SMAD2/3 (#8685), and
GAPDH-HRP (#3683) were purchased from Cell Signaling
Technologies (Massachusetts, United States). Antibodies
targeting pSmad3Ser423/425 (#ab52903) were purchased from
Abcam (Cambridge, United Kingdom). Antibodies targeting
Filamin C (1:2,000) were purchased from Sigma Aldrich.
TMEPAI was detected using an anti-PMEPA1/TMEPAI
antibody (#85829 Santa Cruz Biotechnology, United States)
at 1:1000. Bound primary antibodies were detected by
incubation with HRP-conjugated secondary rabbit (#7074,
Cell Signaling Technologies), mouse (#NXA931V, Amersham,
United Kingdom), or goat antibodies (#P0448, Agilent/Dako,
United States) in 5% skim milk powder or 1% TBS-T for
1 h. Chemiluminescence was detected using ECL western
blotting detection reagents (GE Healthcare, Buckinghamshire,
United Kingdom) and Immobilon Forte western HRP substrate
(Merck, New Jersey, United States).
Production of AAV Vectors
cDNA constructs encoding TMEPAI or activin A (ActA)
were cloned into AAV expression plasmids consisting of a
cytomegalovirus (CMV) or the tetracycline response element
(TRE) promoter and SV40 poly-A region flanked by AAV2
terminal repeats. Viral vector production was performed as
described previously (Blankinship et al., 2004). Briefly, HEK-
293 cells were plated at a density of 7.2–8.5 × 106 cells
on a 15 cm culture dish and incubated for 8–16 h. The
cells were then transfected with 22.5 µg of a vector genome-
containing plasmid and 45 µg of the packaging/helper plasmid
pDGM6 using calcium phosphate precipitation. At 72 h post
transfection, the media and cells were collected and lysed via
three freeze-thaw cycles before 0.22 µm clarification (Merck).
Purification of viral vector particles from crude lysates was
performed using affinity chromatography via heparin affinity
column (HiTrap, Amersham) and ultracentrifugation overnight
prior to re-suspension in sterile physiological Ringer’s solution.
The purified vector preparations were titered with a customized
sequence-specific quantitative PCR-based reaction (Thermo
Fisher Scientific).
Animal Experiments
All experiments were conducted in accordance with the relevant
code of practice for the care and use of animals for scientific
purposes (National Health and Medical Council of Australia).
All experimental protocols were approved by the Alfred Medical
Research and Education Precinct Animal Ethics Committee
(AMREP AEC) and University of Melbourne Animal Ethics
committee. Cohorts of 8-week-old C57Bl/6J mice were obtained
from the breeding colony maintained by the AMREP Animal
Services facility (Melbourne, Australia), the founders of which
were sourced from the Jackson Laboratory. Cohorts of 7-week-
old BALB/c mice were sourced from the Walter and Eliza Hall
Institute Bioservices Kew Division. Mice were fed standard
chow diets unless otherwise stated, with access to drinking
water ad libitum while housed under a 12:12-h light dark cycle.
All surgical procedures were performed on mice placed under
general anesthesia via inhalation of isoflurane in medical oxygen
supported by post-operative analgesia. AAV doses administered
to mice were determined from dose optimization experiments.
AAV:TMEPAI was administered to mice at a dose of 1 × 109
vg. For studies involving the over-expression of activin A, a
tetracycline-inducible gene expression construct (AAV:TetOn)
and a TetOn-responsive ActA (AAV:TRE-ActA) construct were
administered at doses of 1 × 1010 vg and 1 × 109 vg,
respectively. Control treatments consisted of delivery of a viral
vector lacking a functional gene (Con) into the contralateral
limb at equivalent vector genome doses. Vectors were diluted
in 30 µl of Hank’s buffered saline solution and injected
into the anterior compartments of the lower hind limb of
anesthetized mice. Following AAV:TetOn and AAV:TRE-ActA
administration, mice were provided standard chow containing
600 mg/kg doxycycline (Specialty Feeds), to facilitate sustained
gene expression. C57Bl/6J mice administered AAV:TRE-ActA,
AAV:TetOn and AAV:TMEPAI were analyzed 4 weeks after
treatment. Implantation of C26 solid tumor tissue into the flank
of BALB/c mice was performed, as previously described (Aulino
et al., 2010; Winbanks et al., 2016). Tumor-bearing mice were
treated with AAV:TMEPAI and AAV:Control at the time of
tumor implantation. The experimental endpoint was determined
by an ethical criterion of ∼25% loss of initial body mass. At
the experimental endpoint, mice were humanely euthanized via
overdose of sodium pentobarbitone (100 mg/kg) or cervical
dislocation. Skeletal muscles, tissues and organs were excised
rapidly and weighed before subsequent processing.
Skeletal Muscle Histology
Portions of harvested muscles were placed in OCT cryoprotectant
(ProSciTech, Queensland, Australia) and frozen in liquid
nitrogen-cooled isopentane. Frozen samples were cryosectioned
at 10 µm thickness for hematoxylin and eosin staining as
previously described (Hagg et al., 2016). Sections were mounted
using DePeX mounting medium (VWR, Leicestershire, England)
and imaged at room temperature using a U-TV1X-2 camera
mounted to an IX71 microscope and a PlanC 10X/0.25
objective lens (Olympus). Images of sections were obtained using
acquisition software (DP2-BSW, Olympus). Analysis of myofibre
diameter was performed on muscle samples cryosectioned at
8 µm thickness. Sections were incubated in FITC blocking buffer
(Thermo) for 30 min and then in Alexa Fluor 555-conjugated
Wheat Germ Agglutinin (WGA; diluted in PBS) for 2 h. Sections
were stained with DAPI, mounted in Mowiol 4-88 and imaged
using a fluorescence microscope (Axio Imager M2, Zeiss). The
minimum Feret’s diameter of muscle fibers was determined by
measuring at least 400 fibers per mouse muscle, using ImageJ
software (United States National Institutes of Health, Bethesda,
MD, United States).
Quantitative PCR Analysis of Target
Genes
Total RNA was isolated from skeletal muscles using TRIzol
(Thermo Fisher Scientific) according to manufacturer’s
instructions. First, 1 µg of RNA was reverse transcribed
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using the High Capacity RNA-to-cDNA kit (Thermo Fisher
Scientific). Gene expression was analyzed by qRT-PCR using
SYBR primers (Sigma and Thermo Fisher Scientific) and
Real-Time PCR detection (CFX384, Bio-Rad). Target gene
expression was normalized to Hprt. Data were analyzed using
the 11CT method of analysis and are presented as fold change
of the control sample (expressed as 1). Oligonucleotide primer
sequences used are listed in Table 1.
Experimental Design and Statistical
Analysis
In vitro studies were replicated three times. In vivo studies were
performed once. Exclusion criteria for animals were applied in
the case of death, cannibalism or tumor ulceration. Exclusion
criteria for samples were applied in the case of histological
artifacts (freeze- and sectioning-damage) and RNA or protein
degradation. One- and two-way ANOVAs were used to assess
statistical differences between more than two conditions, with
the Tukey’s post-hoc test used for comparisons between the
specific group means (GraphPad Prism v.6, La Jolla, CA,
United States). Data are presented as the means ± SEM.
Comparisons between two conditions utilized the Student’s t-test.
Statistically significant changes are denoted by asterisks, level of
significance is outlined in individual figure legends. Significance
denoted by ∗∗∗∗p < 0.0001, ∗∗∗p < 0.001, ∗∗p < 0.01, and
∗p < 0.05.
RESULTS
TMEPAI Inhibits the in vitro Activity of
Multiple SMAD2/3-Activating Ligands
In previous studies conducted by our laboratories, transcriptional
profiling indicated that skeletal muscle expression of TMEPAI
mRNA (Pmepa1) increased following exposure to activin A
(Chen et al., 2014) and decreased when activin and/or myostatin
signaling pathways were inhibited (Chen et al., 2017). In
this study, qPCR analysis of mouse tibialis anterior (TA)
muscles injected with AAV:ActA confirmed that TMEPAI
transcription increased markedly (6-fold) in response to activin
A expression (Supplementary Figure 1A). This evidence
supports the hypothesis that activin A, like TGF-β1, can
transcriptionally activate TMEPAI, likely via their shared
SMAD2/3 intracellular pathway.
TMEPAI provides negative feedback for TGF-β1-mediated
SMAD2/3 signaling (Watanabe et al., 2010; Nakano et al.,
TABLE 1 | Oligonucleotide sequences used to perform qRT-PCR.







2014), however, its ability to restrict the activity of related
SMAD2/3 activators has not been explored. To test this
hypothesis, we transfected cells with constructs expressing
wild-type TMEPAI and versions containing mutations in the
SIM and PY1/PY2 domains implicated in protein-protein
interactions, (Figures 1A,B) and examined SMAD2/3 signaling
activity in response to ligand exposure (Figures 1C–G). We
found that TMEPAI also suppresses SMAD2/3-induced luciferase
expression triggered by myostatin, activin A, activin B, and GDF-
11, in addition to TGF-β1 (Figures 1C–G). Transient transfection
of cells with constructs expressing TMEPAI (Figure 1B)
exerted inhibitory activity via the tryptophan-rich SIM domain
(Figure 1A), as mutation of this region (PPNR to PPAA)
abolished the ability of TMEPAI to block luciferase activity
induced by all ligands tested (Figures 1C–G and Table 2). In
contrast, flanking PY1/PY2 motifs within TMEPAI, thought to
mediate interactions with the ubiquitin ligase NEDD4 (Watanabe
et al., 2010), were not required for TMEPAI inhibitory activity
against these ligands (Figures 1C–G). Mechanistically, TMEPAI
blocks both endogenous SMAD2 and SMAD3 pathways,
as shown by suppression of activin A-induced SMAD2/3
phosphorylation in HEK293T cells (Figures 1H,I). TMEPAI also
blocked TGFβ1-induced SMAD3 phosphorylation in HEK293T
cells, however, the cells were unresponsive to TGFβ1-induced
SMAD2 activation (Figures 1H–K). These findings demonstrate
that TMEPAI can inhibit SMAD2/3 activation by myostatin,
activin A, activin B and GDF-11 via protein interactions
dependent on the TMEPAI SIM domain.
TMEPAI Promotes Skeletal Muscle
Hypertrophy and Blocks Activin
A-Mediated Muscle Wasting in vivo
Basal SMAD2/3 activation by endogenous myostatin and activins
restricts muscle growth (Chen et al., 2017). Additionally,
overexpression of myostatin, activin A, and activin B, but not
TGF-β1, induces muscle atrophy (Chen et al., 2014). Therefore,
we sought to test the hypothesis that increased expression of
TMEPAI in muscle would counteract the ligands that negatively
regulate muscle mass via SMAD2/3 activation. Here, we found
that delivery of AAV:TMEPAI to the TA hindlimb muscles
of mice promoted muscle hypertrophy, as demonstrated by a
12% increase in TA mass (Figures 2A,B) and 16% increase in
muscle fiber size (Figures 2C,D). We have shown that elevated
circulating levels of activin A, similar to those observed in
patients with cancer cachexia (Loumaye et al., 2015) and in mouse
models of cancer cachexia, can induce profound muscle wasting
(Chen et al., 2014). Therefore, we examined whether TMEPAI
could protect skeletal muscle against activin A-induced atrophy.
Examination of C57Bl/6J male mice 4 weeks after intramuscular
injection of an AAV vector expressing activin A (AAV:ActA)
identified a 30% reduction in TA muscle mass compared
with contralateral muscles (Figures 2A,B). In contrast, co-
delivery of AAV:TMEPAI with AAV:ActA attenuated activin A-
induced loss of muscle mass (Figures 2A,B). Histological analysis
indicated that TMEPAI protected muscle fibers from activin
A-mediated atrophy (Figures 2C,D). In terms of mechanism,
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FIGURE 1 | TMEPAI inhibits the in vitro activity of multiple SMAD2/3 ligands via its SIM domain. (A) Schematic model of TMEPAI noting transmembrane (TM),
SMAD2/3 inhibitory domain, pAkt PY motifs (PY) and placement of an inserted polyhistidine (HIS) tag. (B) Expression of TMEPAI variants in transfected HEK293T
mammalian cells. Reduced cell lysates were probed with an anti-TMEPAI antibody. Multiple TMEPAI protein species are likely owing to differential posttranslational
modifications. (C–G) The ability of TMEPAI to block ligands that signal through SMAD2/3 was determined using a SMAD2/3 responsive luciferase reporter assay in
HEK293T cells. Cells were transfected with plasmids encoding for the luciferase reporter and increasing doses of TMEPAI, then stimulated with the ligands (C)
activin A, (D) activin B, (E) GDF-11, (F) Myostatin, and (G) TGF-β1. Luciferase activity was determined as a measure of SMAD2/3 induction (n = 3
samples/treatment, representative result of n = 3 replicates). (H, I) Western blot analysis of HEK293T lysates revealing that inactivation of the SIM domain in TMEPAI
inhibits the ability of TMEPAI to block activin A-induced endogenous SMAD2 and SMAD3 phosphorylation. (J, K) TMEPAI also blocks TGFβ1-induced endogenous
SMAD3 phosphorylation, but not SMAD2 in HEK293T cells. For western blots, n = 3 samples/treatment condition, ***p < 0.001 and **p < 0.01.
we analyzed SMAD3 phosphorylation in the TA muscles of
mice expressing activin A in the presence, or absence, of
TMEPAI. Western blot analysis of muscle lysates indicated
that TMEPAI suppressed activin A-mediated phosphorylation
of pSMAD3 (Figures 2E–G). Additionally, TMEPAI potently
inhibited activin-induced upregulation of SMAD2/3-target genes
Cyr61 and Igfn1 (Figures 2H,I). Together, these in vivo
studies demonstrate that TMEPAI inhibits the SMAD3-mediated
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TABLE 2 | Luciferase assay data – Area Under the Curve analyses.
WT TMEPAI SIM TMEPAI PY1 + PY2
Activin A 192.1 ± 7.9 368 ± 12.8**** 202 ± 9ns
Activin B 147.2 ± 6.1 307.8 ± 8.9**** 177 ± 6ns
GDF11 169.1 ± 4.8 328.9 ± 6.1**** 205 ± 4ns
Myostatin 184.4 ± 5.1 304.3 ± 14.3*** 199 ± 9ns
TGF-β1 117.7 ± 18.2 178.9 ± 9.1*** 126 ± 6ns
Total Area Under the Curve (arbitrary values) was compared for mutant TMEPAI
forms (SIM and PY1 + PY2) relative to wild type TMEPAI. Values are total
area ± standard error. Significance was determined using two-way ANOVAs with
Tukey’s Post Hoc analysis (n = 3 samples). ****p < 0.0001, ***p < 0.001, and
ns = not significant.
transcriptional response initiated by exogenous, activin A,
thereby, protecting muscle mass.
TMEPAI Preserves Muscle Mass in a
Mouse Model of Cancer Cachexia
As myostatin and activins have been implicated in the
pathogenesis of cancer cachexia, we next sought to determine if
TMEPAI could prevent loss of muscle mass in a mouse model
of cancer cachexia, induced by the subcutaneous growth of
an implanted colon-26 (C26) carcinoma in male BALB/c mice
(Aulino et al., 2010; Zhou et al., 2010; Winbanks et al., 2016).
In the absence of tumor growth, intramuscular injection of
AAV:TMEPAI promoted a significant increase in TA mass (21%)
and fiber size (20%) in BALB/c mice (Figures 3A,B), which was
similar to the changes observed in C57Bl/6J mice (Figures 2A,B).
BALB/c mice bearing C26 tumors displayed a 32% reduction
in TA mass, however, intramuscular administration of TMEPAI
significantly attenuated muscle loss (Figures 3A,B). TMEPAI-
expressing TA muscles in C26 tumor-bearing mice were on
average only 12% reduced in mass when compared with
the muscles of tumor-free mice (Figures 3A,B). Histological
analysis supported these findings, demonstrating a greater
average fiber diameter in muscles from C26 tumor-bearing mice
administered AAV:TMEPAI, compared to contralateral limb
muscles administered AAV:Control (Figures 3C,D). This average
myofibre size was larger than that observed in the TA muscles
of tumor-free control mice (Figures 3C,D). Phosphorylation of
SMAD3 was significantly reduced in the presence of TMEPAI
in the muscles of C26 tumor-bearing mice (Figures 3E–
G), and TMEPAI expression also attenuated transcriptional
activation of SMAD2/3-target genes in C26 tumor-bearing
mice, including Cyr61, and Igfn1 (Figures 3H,I). Additionally,
TMEPAI expression suppressed transcription of the muscle
atrophy genes MuRF-1 and Atrogin-1 (Figures 3J,K).
DISCUSSION
Due to their potent actions on muscle and other tissues,
ligands that signal via activin type II receptors are amongst
the most highly regulated members of the TGF-β superfamily.
Myostatin is secreted in a latent complex with its prodomain
and requires activation by tolloid metalloproteases (Wolfman
et al., 2003). However, activation alone does not guarantee
receptor binding, as numerous extracellular binding proteins,
including follistatin, follistatin-like 3, GASP-1 and GASP-2,
inhibit myostatin activity (Chen et al., 2016a). While activin A
and activin B are secreted in active forms, they too are neutralized
by follistatin and follistatin-related proteins (Nakamura et al.,
1990; Tsuchida et al., 2000) and receptor access can be blocked
by inhibin A and inhibin B (Lewis et al., 2000). Many of these
antagonists and soluble forms of the activin type II receptor
have been shown to increase muscle mass in healthy mice
and mice modeling muscle wasting conditions (Li et al., 2007;
Zhou et al., 2010; Winbanks et al., 2012; Parente et al., 2020).
However, the potential side effects of molecules that target ligands
with broad expression and cell tropism such as activin A/B
(Walton et al., 2012; Campbell et al., 2017) may limit their
therapeutic utility.
An alternative approach to inhibit myostatin/activin activity
is to limit SMAD2/3 phosphorylation downstream of activin type
I receptors in cells of interest. We previously demonstrated the
potential of this approach by using AAV vectors to increase
expression of SMAD7 in skeletal muscle fibers (Winbanks
et al., 2016). SMAD7 prevents SMAD2/3 phosphorylation,
promotes ActRIIB degradation (Hayashi et al., 1997), and
was observed to increase muscle mass in healthy mice and
attenuate wasting in models of cachexia (Winbanks et al.,
2016). Other SMAD2/3 inhibitory proteins, including Smurf,
c-Ski, SnoN, TGIF, and TMEPAI, have primarily been studied
in the context of TGF-β1 signaling (Akiyoshi et al., 1999;
Stroschein et al., 1999; Wotton et al., 1999; Zhu et al.,
1999). However, the recent observation that activin induces
TMEPAI expression in skeletal muscle (Chen et al., 2014)
suggested that this membrane-associated protein may be
involved in an intracellular negative feedback system that
limits the activation of SMAD2/3 and, thereby, helps maintain
muscle homeostasis.
TMEPAI is a membrane- or lysosome-associated protein
that regulates not only TGF-β1 signaling but also androgen
receptor (AR) and phosphatase and tensin homologue deleted on
chromosome 10 (PTEN) activity (Watanabe et al., 2010; Singha
et al., 2014). Regulation of these pathways help to explain a link
between TMEPAI and tumourigenicity, where it has been shown
TMEPAI can either limit cancer progression and metastases
(Singha et al., 2014; Fournier et al., 2015; Li et al., 2015; Du et al.,
2018; Abdelaziz et al., 2019) or promote cancer development
(Rae et al., 2001; Giannini et al., 2003; Vo Nguyen et al.,
2014; Singha et al., 2019). In this study, we demonstrated that
TMEPAI also inhibits myostatin, activin A, activin B and GDF11
signaling, revealing that TMEPAI operates as a general inhibitor
of SMAD2/3-activating ligands in muscle. Overexpression of
TMEPAI specifically in skeletal muscle enhanced muscle mass
by increasing fiber size and abrogated muscle atrophy induced
by overexpression of activin A. Moreover, TMEPAI expression
attenuated muscle wasting in an established mouse model of
cancer cachexia.
In muscles overexpressing activin A, TMEPAI inhibits
SMAD3 (and potentially SMAD2) phosphorylation and reduces
the activin transcriptional response, as evident by a significant
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FIGURE 2 | TMEPAI promotes skeletal muscle hypertrophy and blocks activin A-mediated muscle wasting in vivo. (A, B) 4 weeks after the TA muscles of
6–8-week-old C57Bl/6J were injected with AAV vectors encoding TMEPAI and/or activin A (or equivalent doses of AAV lacking the transgene), muscles were excised
to measure mass (n = 6 samples per treatment condition). (C, D) Mean muscle fiber diameter and representative morphology according to haematoxylin and eosin
staining (n = 5 samples per treatment condition). (E) Protein lysates of muscles were subjected to western blot analysis of intracellular target pSMAD3 and (F, G)
protein abundance was quantified using densitometric methods (n = 6 samples per treatment condition). (H, I) Expression of SMAD2/3-target genes Cyr61 and
Igfn1 in muscles (n = 4–6 per treatment group). ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.
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FIGURE 3 | TMEPAI prevents localized muscle wasting in a mouse model of cancer cachexia. (A, B) 7-week-old BALB/c mice implanted with subcutaneous
Colon-26 tumors (or subjected to sham surgery) were administered TA muscle injections of AAV vector expressing TMEPAI (or control vector). At experimental
endpoint, TA muscles were harvested and weighed (n = 6–7 samples per treatment group). (C, D) Muscle fiber size and representative morphology indicated by
wheat germ agglutinin labeling of TA muscle cryosections (n = 5 samples per treatment group). (E) Western blot analysis of muscle protein lysates for assessment of
SMAD3 phosphorylation, and (F, G) protein abundance quantified by densitometry (n = 6–7 samples per treatment group). (H, I) The transcription of
SMAD2/3-target genes and (J,K) key muscle atrophy-related genes in the muscles from the aforementioned mice (n = 6–7 samples per treatment group).
****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.
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decrease in the expression of activin-responsive genes (e.g., Cyr61
and Igfn1). Similarly, in the muscles of C26 tumor-bearing
mice, where activin A serum concentrations are increased (Chen
et al., 2016b), SMAD3 phosphorylation is significantly reduced by
TMEPAI. In support, expression of SMAD2/3 target genes Cyr61
and Igfn1 is also reduced in the muscles of C26 tumor-bearing
mice in response to TMEPAI expression. Further, in tumor-
bearing mice, TMEPAI expression suppressed transcriptional
activation of muscle atrophy genes, Murf-1 and Atrogin-1, likely
contributing to its protective effects against muscle wasting.
However, as TMEPAI can also activate SMAD-independent AR
and PTEN/Akt signaling pathways (Itoh and Itoh, 2018), it is
possible that additional mechanisms may contribute to TMEPAI-
mediated muscle hypertrophy in these mice. Mechanistically, we
showed that TMEPAI exerted its inhibitory activity via a short
SIM domain, which lies within its C-terminal cytoplasmic region.
Targeted disruption of the SIM domain inhibited the ability of
TMEPAI to block activin A, activin B, myostatin and GDF11
activity. Conversely, the flanking PY motifs were dispensable
for inhibition of SMAD2/3 signaling. This is important because
the PY motifs mediate the interaction of TMEPAI with other
signaling pathways (Watanabe et al., 2010) and suggest that the
TMEPAI (PY) variant could be utilized to specifically inhibit
SMAD2/3 signaling in skeletal muscle.
The data presented here demonstrate that TMEPAI gene
delivery to skeletal muscle can attenuate activin signaling and
preserve or increase muscle mass. As inhibition of activin
signaling has also been shown to positively regulate metabolic
processes (Han et al., 2019; Davey et al., 2020), expression of
TMEPAI may also confer benefits in settings of metabolic disease.
The signaling actions of TMEPAI within muscle fibers suggest
that a muscle-restricted intervention could avoid the off-target
effects of extracellular ligand traps, such as soluble ActRIIB. The
findings support future studies to explore the extent to which
systemically administered interventions that increase TMEPAI
expression in skeletal muscles can protect against body-wide
muscle wasting in different disease settings.
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